Clinical Trial Update: Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) [Phase 1]

View source ↗

Summary

Phase 1 study reporting plasma pharmacokinetics and lung penetration of ceftolozane/tazobactam in adults with pneumonia, completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Ceftolozane/Tazobactam (ceftolozane/tazobactam)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Critically Ill, Pneumonia | Phase 1 | Status: COMPLETED | Results posted: 2019-02-15